QUEST informs readers of the latest advances in urologic prostate cancer research, especially detection, prevention, and treatment.
A study including several members of PCASP (Prostate Cancer Active Surveillance Project) on which Dr. Catalona is a co-author reported on the variation in the use of active surveillance for low-risk prostate cancer in the U.S. They evaluated 20,809 patients…
Induced pluripotent stem cell project with Cedars Sinai Dr. Catalona is collaborating with Dan Theodorescu, MD Ph.D. (a cancer center director and a cancer researcher) and Clive Svendsen, Ph.D. (a neuroscientist with expertise in induced pluripotent stem cell technology) at…
Screening for prostate cancer is burdened by a high rate of overdiagnosis. The most appropriate algorithm for population- based screening is unknown. This study invited 37,887 men who were 50-60 years of age to undergo regular PSA screening. Participants with…
Each year, the American Cancer Society estimates the number of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes. In 2023, 1,958,310 new cancer cases and 609,820 cancer…
Enter a “Risen Star”: Burcu F. Darst, PhD Did you ever wish you could see your genetic future – what awaits you in your life’s road and what could you do to avert a potential danger to your long life…
Prostate cancer is the most common cancer in men. Age, family history of prostate cancer, and germline variation are the most established risk factors, with as much as 57% of the variability in prostate cancer risk estimated to be due…
All living things, including humans, are made of cells. Each tissue and organ of the body contain cells that are specialized to perform specific jobs-the brain contains neurons, the eyes contain light-detecting cells and so on. All human life begins…
Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) is inceasingly included in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). In this analysis, 184 patients were treated with 177Lu-PSMA RLT. Response to treatment was defined as decrease in PSA…
There is no standard follow-up protocol for men with a negative evaluation with systematic biopsies and multiparametric MRI (mpMRI) and a persistent clinical suspicion of prostate cancer. This study assessed the proportion of clinically significant prostate cancers during follow-up after…
Treatment with Olaparib was associated with a reduction in pain and improvement in health-related quality of life compared with physician’s choice of hormone therapy (enzalutamide or abiraterone) in patients with metastatic castration-resistant prostate cancer (mCRPC) and DNA-repair deficiency genetic mutations…
